



PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|------------------|--------------------------|------------------------|------------------------|-----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/575,671 | | |
| | | Filing Date | October 8, 2004 (I.A.) | | |
| | | First Named Inventor | Bradley T. Messmer | | |
| | | Art Unit | to be determined | | |
| Examiner Name | to be determined | | | | |
| Sheet | 1 | of | 3 | Attorney Docket Number | 50425/245 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | BORCHE L. et al., "Evidence That Chronic Lymphocytic Leukemia B Lymphocytes Are Frequently Committed to Production of Natural Autoantibodies"; Blood, 1990, Vol. 76, No. 3, pp 562-69. | |
| | | BREZINSCEK H-P. et al., "Analysis of the Human V _H Gene Repertoire. Differential Effects of Selection and somatic Hypermutation on Human Peripheral CD5+/IgM+"; The Journal of Clinical Investigation, 1997, Vol. 99, No. 10, pp 2488-2501. | |
| | | CHIORAZZI N. and FERRARINI M., "Immunoglobulin Variable Region Gene Characteristics and Surface Membrane Phenotype Define B-CLL Subgroups with Distinct Clinical Courses"; Chronic Lymphoid Leukemias, 2001, B.D. Cheson, editor, Marcel Dekker, NY, pp 81-9109. | |
| | | CHIORAZZI N. and FERRARINI M., "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor"; Annual Review of Immunology, 2003, Vol. 21, pp 841-94. | |
| | | DAMLE R.N. et al., "Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia"; Blood, 1999, Vol. 94, No. 6, pp 1840-47. | |
| | | FAIS F. et al., "Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutates Antigen Receptors"; The Journal of Clinical Investigation, 1998, Vol. 102, No. 8, pp 1515-25. | |
| | | FAIS F. et al., "Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas"; Leukemia, 1999, Vol. 13, pp 1093-99. | |
| | | GHIA P. et al., "Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly"; Blood, 2004, Vol. 103, No. 6, pp 2337-42. | |
| | | GHIOTTO F. et al., Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia"; The Journal of Clinical Investigation, 2004, Vol. 113, No. 7, pp 1008-16. | |
| | | HAMBLIN T.J. et al., "Unmutated IG V _H Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia"; Blood, 1999, Vol. 94, No. 6, pp 1848-54. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|------------------|--------------------------|------------------------|------------------------|-----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/575,671 | | |
| | | Filing Date | October 8, 2004 (I.A.) | | |
| | | First Named Inventor | Bradley T. Messmer | | |
| | | Art Unit | to be determined | | |
| Examiner Name | to be determined | | | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | 50425/245 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | HE X. et al., "VH3-21 B Cells Escape from a State of Tolerance in Rheumatoid Arthritis and Secrete Rheumatoid Factor"; Volecular Medicine, 1995, Vol. 1, No. 7, pp 768-80. | |
| | | ISAACSON P.G., "Gastric MALT lymphoma: From concept to cure"; Annals of Oncology, 1999, Vol. 10, pp 637-45. | |
| | | JOHNSON T.A. et al., IG VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features"; The Journal of Immunology, 1997, Vol. 158, No. 1, pp 235-46. | |
| | | KIRKHAM P.M. et al., "Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding"; The EMBO Journal, 1992, Vol. 11, No. 2, pp 603-9. | |
| | | KUMAR S. et al., "Anti-cardiolipin/β-2 glycoprotein activities co-exist on human anti-DNA antibody light chains"; Molecular Immunology, 2003, Vol. 40, No. 8, pp 517-30. | |
| | | PASCUAL V. et al., "VH Restriction Among Human Cold Agglutinins. The Vh4-21 Gene Segment Is REquired to Encode Anti-I and Anti-i Specificities"; The Journal of Immunology, Vol. 149, No. 7, pp 2337-44. | |
| | | POTTER M., "Antigen-Binding Myeloma Proteins of Mice"; Advances In Immunology, 1977, Vol. 25, pp 141-211. | |
| | | PUGH-BERNARD A.E. et al., "Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance"; The Jouranl of Clinical Investigation, Vol. 108, No. 7, pp 1061-70. | |
| | | RAWSTRON A.C. et al., "Monoclonal B lymphocytes with the characteristics of "Indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts"; Blood, 2002, Vol. 100, No. 2, pp 635-39. | |
| | | SCHRODER, JR., H.W. and DIGHIERO G., "The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire." Immunology Today, 1994, Vol. 15, No. 6, pp 288-94. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|------------------|--------------------------|------------------------|------------------------|-----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/575,671 | | |
| | | Filing Date | October 8, 2004 (I.A.) | | |
| | | First Named Inventor | Bradley T. Messmer | | |
| | | Art Unit | to be determined | | |
| Examiner Name | to be determined | | | | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 50425/245 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | SCOTT M.G. et al., "Clonal Characterization of the Human IgG Antibody Repertoire To Haemophilus influenzae Type b Polysaccharide. III. A Single VKII Gene and One of Several JK Genes Are Joined by an Invariant Arginine to Form the Most Common L Chain V Region"; The Journal of Immunology, 1989, Vol. 143, No. 12, pp 4110-16. | |
| | | SILVERMAN G.J. et al., "Idiotypic and Subgroup Analysis of Human Monoclonal Rheumatoid Factors. Implication for Structural and Genetic Basis of Autoantibodies in Humans"; The Journal of Clinical Investigation, 1998, Vol. 82, pp 469-75. | |
| | | STHOEGER Z.M. et al., "Mechanism of Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia"; American Journal of Hematology, 1993, Vol. 43, pp 259-64. | |
| | | TOBIN G. et al., "Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia"; Blood, 2002, Vol. 99, No. 6, pp 2262-64. | |
| | | TOBIN G. et al., "Chronic lymphocytic leukemias utilizing the VH-3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope"; Blood, 2003, Vol. 101, No. 12, pp 4952-57. | |
| | | VALETTA A. et al., "A Subset of IgG+ B-CLL Cells Expresses Virtually Identical Antigen Receptors that Bind Similar Peptides. Evidence for Antigen-Selection in the Leukemogenic Process"; Abstract #1784, Poster Board#/Session: 456-III. (cited incorrectly in International Search Report of PCT/US2004/033176). | |
| | | Carter, P., "Improving the Efficacy of Antibody-Based Cancer Therapies"; Nature Reviews, Cancer, November 2001, Vol. 1, No. 2, pp 118-129. | |
| | | Supplementary European Search Report issued March 20, 2008 in connection with European Patent Application No. EP 04794503.5. | |
| | | July 14, 2005 Written Opinion and International Search Report issued in connection with PCT International Patent Application No. PCT/US2004/033176. | |
| | | April 10, 2006 International Preliminary Report on Patentability issued in connection with PCT International Patent Application No. PCT/US2004/033176. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.